Core Viewpoint - Guoen Co., Ltd. is advancing its internationalization strategy by issuing H-shares at a price of HKD 36.00 per share, set to be listed on February 4, 2026, on the Hong Kong Stock Exchange, aiming to enhance its capital operation platform and support the dual circulation strategy in China [2]. Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and focuses on two core industries: large-scale chemicals and health [3]. - The company was listed on the Shenzhen Stock Exchange in 2015 [3]. Group 2: Health Sector - In the health sector, Guoen holds a controlling stake in Dongbao Biological, which specializes in collagen products, including gelatin, blood plasma gelatin, collagen protein, and beauty products, with applications in medicine, beauty, health, and food [4]. Group 3: Chemical Sector - In the chemical sector, Guoen has developed a cluster of new chemical materials, including green petrochemicals, organic polymer modifications, and biodegradable materials, establishing long-term partnerships with major clients like Hisense, Gree, TCL, Huawei, BOE, and CATL [5]. - The company has announced a new project for producing 20,000 square meters of aviation-grade acrylic glass, with an investment of CNY 560 million, aimed at becoming a key supplier of aviation transparent materials in China [6]. Group 4: Production Capacity - Current production capacities include: - Organic polymer modification: 1.08 million tons, with 300,000 tons under construction - Organic polymer composite materials: 400,000 tons, with 100,000 tons under construction - Green petrochemical materials: 900,000 tons, with 1.02 million tons under construction - Polystyrene (PS): 600,000 tons per year from the first phase of a project, with a second phase of 400,000 tons underway [7][8]. Group 5: Financial Performance - In 2024, Guoen achieved a total revenue of CNY 19.22 billion, a year-on-year increase of 10.21%, with a net profit of CNY 676 million, up 45.18% [9]. - For the first three quarters of 2025, the company reported total revenue of CNY 15.497 billion, a 9.44% increase year-on-year, and a net profit of CNY 615 million, up 34.24% [10].

Core Viewpoint - Guoen Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operation platform and accelerate the establishment of a dual circulation pattern in the domestic and international markets [1] Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and is headquartered in Qingdao, focusing on two core industries: large chemicals and health [1] - The company operates a vertically integrated industrial platform and implements a "one body, two wings" development strategy, forming a cluster of new chemical materials [1] - The company has a strong presence in the health sector through its subsidiary Dongbao Biological, which produces a variety of products including gelatin and collagen [1] Group 2: Chemical Industry Segment - The large chemical segment generated revenue of 17.369 billion yuan in 2024, accounting for 90.38% of total revenue, with a year-on-year growth of 11.62% [3] - The company has established long-term stable partnerships with major clients such as Hisense, Gree, TCL, Huawei, BOE, and CATL [3] - Current production capacities include 1.08 million tons for organic polymer modified materials, 400,000 tons for organic polymer composite materials, and 900,000 tons for green petrochemical materials [4] Group 3: Product Development and Market Strategy - The company is enhancing its market share in the new energy vehicle sector by improving the performance of modified materials such as PP, PC, ABS, and PA [2] - In the energy storage battery sector, the company is advancing the application of flame-retardant and anti-explosion materials [2] - Future plans include expanding production capacities for polystyrene and developing new products like high-performance polyolefin elastomers and biodegradable materials [5] Group 4: Financial Performance - In 2024, the health segment generated revenue of 885 million yuan, accounting for 4.6% of total revenue [5] - Overall, the company achieved a total revenue of 19.22 billion yuan in 2024, a year-on-year increase of 10.21%, with a net profit of 676 million yuan, up 45.18% [5] - The first quarter of 2025 reported total revenue of 4.412 billion yuan, a slight decrease of 0.23% year-on-year, with a net profit of 111 million yuan, down 9.79% [6]

Core Viewpoint - Guoen Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operation platform and accelerate the construction of a dual circulation pattern in the domestic and international markets [1] Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and is headquartered in Qingdao, focusing on two core industries: large chemicals and health [1] - The company operates a vertically integrated industrial platform and implements a "one body, two wings" development strategy, forming a chemical new materials industry cluster [1] - The company has a strong presence in the health sector through its subsidiary Dongbao Biological, which specializes in gelatin and collagen products [1] Group 2: Chemical Sector Performance - In the new energy vehicle sector, the company is increasing market share in modified materials such as PP, PC, ABS, PA, and PMMA [2] - The company has a current production capacity of 1.08 million tons for organic polymer modified materials, 400,000 tons for organic polymer composite materials, and 900,000 tons for green petrochemical materials [2] - In 2024, the chemical sector achieved revenue of 17.369 billion yuan, accounting for 90.38% of total revenue, with a year-on-year growth of 11.62% [3] Group 3: Health Sector Performance - The health sector, led by Dongbao Biological, has an annual gelatin production capacity of 13,500 tons and a future capacity of 70 billion capsules [4] - In 2024, the health sector generated revenue of 885 million yuan, representing 4.6% of total revenue [4] Group 4: Overall Financial Performance - In 2024, Guoen Co., Ltd. reported total revenue of 19.220 billion yuan, a year-on-year increase of 10.21%, with a net profit of 676 million yuan, up 45.18% year-on-year [4] - The company reported a slight decline in revenue and net profit in Q1 2025 compared to the same period last year, with total revenue of 4.412 billion yuan, down 0.23% year-on-year [4]